Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase Three Clinical Trials of Trivalent Rotavirus Genetic Reassortment Vaccine

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2012 by Center for Disease Control and Prevention, Henan Province.
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
Center for Disease Control and Prevention, Henan Province Identifier:
First received: November 20, 2012
Last updated: November 28, 2012
Last verified: November 2012
Assessment and evaluation the rotavirus gastroenteritis prevention effect and severe rotavirus diarrhea reducing effectiveness of human body, which inoculate trivalent rotavirus genetic reassortment vaccine.

Condition Intervention Phase
Placebo Control Design
Biological: trivalent rotavirus genetic reassortment vaccine
Biological: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Prevention

Further study details as provided by Center for Disease Control and Prevention, Henan Province:

Primary Outcome Measures:
  • Antibody titer differences in serum [ Time Frame: 4 weeks after full vaccination ]
  • Incidence differences of rotavirus diarrhea [ Time Frame: 2 years after full vaccination. ]

Enrollment: 10020
Study Start Date: August 2012
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: trivalent rotavirus genetic reassortment vaccine
2ml of rotavirus genetic reassortment vaccine by mouth every month for three month
Biological: trivalent rotavirus genetic reassortment vaccine
Placebo Comparator: Placebo
2ml of placebo by mouth every month for three month
Biological: Placebo


Ages Eligible for Study:   6 Weeks to 13 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 6 to 13 weeks aged healthy baby;
  • Guardian volunteer to participate in the study and sign informed consent;
  • have use thermometer as required and the ability to fill in the diary table;
  • Subjects guardian can abide by the requirements of clinical research scheme;
  • The past has not been vaccinated rotavirus vaccine;
  • Normal term eutocia, birth weight up to standard;
  • Axillary temperature is 37.0 ℃ or less.

Exclusion Criteria:

  • With allergy, convulsion, epilepsy, encephalopathy and spirit history or the family history;
  • Be allergy to any ingredients in the vaccine;
  • Known immunology function damage or low person;
  • Immunosuppressant therapy Accepter;
  • Suffering from congenital malformation and developmental disorder;
  • Known or suspected also suffer from diseases including: digestive system disease, respiratory system disease, acute infection, mother or I have HIV infection, cardiovascular diseases, malignant tumor during treatment, skin disease;
  • Inoculation other vaccine within 7 days.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Center for Disease Control and Prevention, Henan Province Identifier: NCT01738074     History of Changes
Other Study ID Numbers: HNCDC-001
Study First Received: November 20, 2012
Last Updated: November 28, 2012

Keywords provided by Center for Disease Control and Prevention, Henan Province:
trivalent genetic reassortment vaccine
Phase three clinical trials

Additional relevant MeSH terms:
Immunologic Factors
Physiological Effects of Drugs processed this record on April 28, 2017